Narumi Maida

Narumi Maida

Auto-generated profile, based on publicly available information

Narumi Maida

Faculty of Pharmaceutical Sciences, Tokyo University of Science, 6-3-1 Niijuku, Katsushika, Tokyo 125-8585, Japan

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2026 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
EHEna Hattanda
Ena Hattanda
NMNarumi Maida
Narumi Maida
KHKaoru Hirose
Kaoru Hirose
KNKayo Nakamura
Kayo Nakamura
HTHidetsugu Tabata
Hidetsugu Tabata
Takehisa HanawaTakehisa Hanawa
Takehisa Hanawa
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by abdominal pain and diarrhea. Although 5-aminosalicylic acid (5-ASA) enemas are widely used, conventional formulations can result in rectal leakage and poor retention, substantially impairing the therapeutic efficacy and quality of life (QOL) of patients. To address these limitations, in this study, we developed a thermoresponsive and mucoadhesive dual-functionality enema system by combining poloxamer with carbopol (CP). This study optimized a thermoresponsive and mucoadhesive rectal gel formulation for 5-ASA and evaluated its physicochemical properties and therapeutic efficacy in experimental ulcerative colitis. The formulation exhibited a gelation temperature of 30-35 °C, indicating its suitability for situ gel formation in the colon. The 1H NMR analysis confirmed minimal interactions between 5-ASA and the polymers. Increasing the CP concentration markedly delayed drug release, likely due to enhanced network entanglement within the gel. Ex vivo evaluation using porcine colonic mucosa indicated reduced leakage and improved adhesion compared with a commercial formulation. Furthermore, in vitro studies using Caco-2 cells showed enhanced retention of the active compounds. These findings indicate that the proposed system enables injectable administration, in situ gelation, strong mucosal adhesion, and gradual release of 5-ASA while maintaining enhanced mucoadhesion and rectal retention, thereby improving retention and therapeutic potential. Furthermore, the administration of the formulation to rats with UC led to a significantly higher anti-inflammatory effect. Thus, the developed approach represents a promising strategy for enhancing treatment efficacy and patient compliance in ulcerative colitis.